Tri Locum Partners’s Quince Therapeutics QNCX Stock Holding History

Tri Locum Partners’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-111	Closed	-$14K	–	80
2022 Q4	$14K	Buy	+111	New	+$18.6K	0.01%	69

Other funds holding QNCX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Tri Locum Partners's QNCX Position: Q1 2023 in Review

Tri Locum Partners sold out of Quince Therapeutics (QNCX) in Q1 2023, closing a stake of 111 shares — an estimated $14K sold.

Tri Locum Partners first reported a position in QNCX in Q4 2022 and held it in 1 quarter. The position peaked at $14K in Q4 2022. 42 funds tracked by Wall St. Rank hold QNCX as of Q1 2023.

Tri Locum Partners reported no remaining Quince Therapeutics position as of Q1 2023 after selling out during the quarter.
Tri Locum Partners sold 111 Quince Therapeutics shares in Q1 2023, an estimated $14K.
Tri Locum Partners first reported a position in Quince Therapeutics in Q4 2022 and held it in 1 quarter.
Tri Locum Partners's Quince Therapeutics position peaked at $14K in Q4 2022.
42 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2023.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.